Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis

BMC Pulmonary Medicine

Table 2 Forced vital capacity outcomes reported in the included trials

	Change in percent predicted FVC (%) or absolute change from baseline (L)						No. with reduction in FVC >10%^{a b}
Source	FVC outcome	Treatment		Placebo		P value	Treatment	Placebo	P value
		No. of participants	Mean (SD)	No. of participants	Mean (SD)		No. (%)	No. (%)
Pirfenidone
Noble et al. 2011 [4] (Capacity 006)	% pred	171	−9.0 (19.6)	173	−9.6 (19.1)	0.501	39 (23)	46 (27)	0.440
Noble et al. 2011 [4] (Capacity 004)	% pred	174	−8.0 (16.5)	174	−12.4 (18.5)	0.001	35 (20)	60 (35)	0.01
Taniguchi et al. 2010 [5]	Litres	104	−0.09 (0.20)	103	−0.16 (0.20)	0.042
Azuma et al. 2005 [6]	Litres	72	−0.03 (0.22)	35	−0.13 (0.19)	0.037	9 (13)	12 (36)	0.003
King et al. 2014 [7] (Ascend)	Litres	278	−0.122 (0.4)	277	−0.262 (0.4)	0.001	46 (16.5)	88 (31.8)	<0.00001
Nintedanib
Richeldi et al. 2011 [25]	% pred	85	−1.04 (9.1)	85	−6.0 (9.4)	<0.001	20 (23.8)	37 (44.0)	0.004
	Litres	85	−0.06 (0.37)	85	−0.23 (0.37)	0.001
Richeldi et al. 2014 [8] (INPULSIS-1)	% pred	307	−2.8 (6.2)	204	−6.0 (6.2)	<0.001	91 (29.5)^c	88 (43.1)	<0.001
	Litres	307	−0.095 (0.22)	204	−0.205 (0.22)	<0.001
Richeldi et al. 2014 [8] (INPULSIS-2)	% pred	327	−3.1 (6.99)	217	−6.2 (6.99)	<0.001	100 (30.4)^e	79 (36.1)^e	0.18
	Litres	327	−0.095 (0.23)	217	−0.205 (0.23)	<0.001
Inhaled NAC
Homma et al. 2012 [24],	Litres	38	−0.09 (0.3)	38	−0.15 (0.2)	0.27
NAC triple therapy
Raghu et al. 2012 [22], (PANTHER)	Litres	77	−0.24 (0.4)	78	−0.23 (0.4)	0.85
NAC
IPFCRN, 2014 [23] (PANTHER)	% Pred ^d	133	−4.37 (7.5)	131	−4.76 (7.3)	0.67
	Litres ^d	133	−0.18 (0.3)	131	−0.19 (0.3)	0.77

In some trials the vital capacity was reported which has been assumed to translate to the FVC.
Where not reported in individual trials measures of variance have been estimated from p-values reported using standard methodology.
^aNumber of participants with a reduction in mean FVC of >10% (or 200 ml where applicable). ^bNumber of participants with a reduction in mean FVC of >10% or death in ASCEND trial [7]. ^cBased on 309 patients in Nintedanib group. ^dFrom longitudinal analysis which adjusts for treatment time, interaction between time and treatment, age, sex, race and height; assumes that data were missing at random and no data were imputed. ^eBased on 329 patients in Nintedanib group and 219 patients in placebo group.

ISSN: 1471-2466